Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Shares Gap Up - Here's What Happened

Key Points

• Shionogi’s ADR shares opened sharply higher, rising from a prior close of $8.47 to $9.07 before settling at $8.71, up 2.5% on trading volume of 3,102 shares.
• Analyst sentiment improved after Jefferies and Goldman Sachs upgraded the stock from “Hold” to “Strong Buy.” MarketBeat reports a consensus rating of “Buy” from three analysts.
• Shionogi exceeded quarterly expectations, reporting EPS of $0.36 versus $0.18 expected and revenue of $1.04 billion versus a $970.69 million consensus estimate.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY - Get Free Report)'s stock price gapped up prior to trading on Tuesday. The stock had previously closed at $8.47, but opened at $9.07. Shionogi & Co., Ltd. Unsponsored ADR shares last traded at $8.71, with a volume of 3,102 shares changing hands.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the company. Jefferies Financial Group raised Shionogi & Co., Ltd. Unsponsored ADR from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, July 14th. The Goldman Sachs Group raised Shionogi & Co., Ltd. Unsponsored ADR from a "hold" rating to a "strong-buy" rating in a research note on Monday, June 15th. Two equities research analysts have rated the stock with a Strong Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, Shionogi & Co., Ltd. Unsponsored ADR presently has a consensus rating of "Buy".

Shionogi & Co., Ltd. Unsponsored ADR Trading Up 2.5%

The company has a 50 day moving average price of $9.11 and a 200 day moving average price of $9.37. The firm has a market cap of $14.77 billion, a price-to-earnings ratio of 8.68, a price-to-earnings-growth ratio of 3.16 and a beta of 0.08. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.00 and a current ratio of 1.14.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY - Get Free Report) last issued its quarterly earnings data on Monday, August 3rd. The company reported $0.36 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.18 by $0.18. Shionogi & Co., Ltd. Unsponsored ADR had a return on equity of 16.13% and a net margin of 46.67%.The firm had revenue of $1.04 billion during the quarter, compared to the consensus estimate of $970.69 million. On average, research analysts expect that Shionogi & Co., Ltd. Unsponsored ADR will post 0.82 earnings per share for the current year.

About Shionogi & Co., Ltd. Unsponsored ADR

Shionogi & Co, Ltd. is a Japan-based research-driven pharmaceutical company headquartered in Osaka. Founded in 1878, the company discovers, develops, manufactures and markets prescription medicines, with a focus on infectious diseases, central nervous system disorders and other areas of unmet medical need.

Shionogi's portfolio includes Xofluza (baloxavir marboxil), an antiviral treatment for influenza, and F. (fostemsavir), an HIV treatment marketed in certain regions. The company also develops medicines for conditions including pain, psychiatric disorders and other diseases, while pursuing research in areas such as antimicrobial resistance and novel anti-infective therapies.

Shionogi primarily serves the Japanese market and has expanded its international presence through subsidiaries, licensing arrangements and commercial partnerships in North America, Europe and other regions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.